» Articles » PMID: 24564171

A Gene Signature Based Method for Identifying Subtypes and Subtype-specific Drivers in Cancer with an Application to Medulloblastoma

Overview
Publisher Biomed Central
Specialty Biology
Date 2014 Feb 26
PMID 24564171
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Subtypes are widely found in cancer. They are characterized with different behaviors in clinical and molecular profiles, such as survival rates, gene signature and copy number aberrations (CNAs). While cancer is generally believed to have been caused by genetic aberrations, the number of such events is tremendous in the cancer tissue and only a small subset of them may be tumorigenic. On the other hand, gene expression signature of a subtype represents residuals of the subtype-specific cancer mechanisms. Using high-throughput data to link these factors to define subtype boundaries and identify subtype-specific drivers, is a promising yet largely unexplored topic.

Results: We report a systematic method to automate the identification of cancer subtypes and candidate drivers. Specifically, we propose an iterative algorithm that alternates between gene expression clustering and gene signature selection. We applied the method to datasets of the pediatric cerebellar tumor medulloblastoma (MB). The subtyping algorithm consistently converges on multiple datasets of medulloblastoma, and the converged signatures and copy number landscapes are also found to be highly reproducible across the datasets. Based on the identified subtypes, we developed a PCA-based approach for subtype-specific identification of cancer drivers. The top-ranked driver candidates are found to be enriched with known pathways in certain subtypes of MB. This might reveal new understandings for these subtypes.

Conclusions: Our study indicates that subtype-signature defines the subtype boundaries, characterizes the subtype-specific processes and can be used to prioritize signature-related drivers.

Citing Articles

Network-Based Methods for Approaching Human Pathologies from a Phenotypic Point of View.

Ranea J, Perkins J, Chagoyen M, Diaz-Santiago E, Pazos F Genes (Basel). 2022; 13(6).

PMID: 35741843 PMC: 9222217. DOI: 10.3390/genes13061081.


Integrated computational analyses reveal novel insights into the stromal microenvironment of SHH-subtype medulloblastoma.

Landry A, Samuel N, Spears J, Zador Z Sci Rep. 2021; 11(1):20694.

PMID: 34667228 PMC: 8526813. DOI: 10.1038/s41598-021-00244-3.


Production of a SCID mouse model of medulloblastoma to explore the therapeutic value of targeting tumor driver genes.

Han Y, Chen M, Wang H Exp Ther Med. 2020; 21(2):108.

PMID: 33335571 PMC: 7739861. DOI: 10.3892/etm.2020.9540.


Kernel Fusion Method for Detecting Cancer Subtypes via Selecting Relevant Expression Data.

Li S, Jiang L, Tang J, Gao N, Guo F Front Genet. 2020; 11:979.

PMID: 33133130 PMC: 7511763. DOI: 10.3389/fgene.2020.00979.


Construction and Validation of a 13-Gene Signature for Prognosis Prediction in Medulloblastoma.

Li C, Zou H, Xiong Z, Xiong Y, Miyagishima D, Wanggou S Front Genet. 2020; 11:429.

PMID: 32508873 PMC: 7249855. DOI: 10.3389/fgene.2020.00429.


References
1.
Visvader J . Cells of origin in cancer. Nature. 2011; 469(7330):314-22. DOI: 10.1038/nature09781. View

2.
Katoh M . WNT/PCP signaling pathway and human cancer (review). Oncol Rep. 2005; 14(6):1583-8. View

3.
Stanton B, Peng L . Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst. 2009; 6(1):44-54. DOI: 10.1039/b910196a. View

4.
Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

5.
Kool M, Koster J, Bunt J, Hasselt N, Lakeman A, van Sluis P . Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008; 3(8):e3088. PMC: 2518524. DOI: 10.1371/journal.pone.0003088. View